Abstract: Low vitamin D status has been associated with increased risk of several cancers and obesity; concurrently, obesity and cancer have been linked to impaired vitamin D status. In both cancer and obesity, selective elimination of cancer cells and adipocytes can result in decreasing tumor size and a long-term reduction in adipose tissue mass. These effects can be achieved through induction of apoptotic cell death. -dependent apoptotic proteases as promising targets for discovery of new therapeutic and preventive agents for cancer and obesity. The concept of maintaining an increased vitamin D status for protecting against cancer and decreasing adiposity also warrants further evaluation.
Introduction
Vitamin D (vitamin D 3 ) is a precursor of the secosteroid hormone 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), which functions via the relatively well-defined genomic and nongenomic mechanisms in a number of cell types, tissues, and organs [1] [2] [3] [4] . Moreover, paracrine and autocrine modes of action of 1,25(OH) 2 D 3 appear to be of importance in some cells [1, 2] . Vitamin D is also defined as a micronutrient and is increasingly often considered of great importance for maintaining good health throughout life and preventing numerous diseases [3, 5] ; these claims, however, have not been sufficiently substantiated.
The essential function of 1,25(OH) 2 D 3 is regulation of cellular Ca 2+ signaling, which is linked to a number of cellular responses [6] [7] [8] . Intracellular Ca 2+ signals triggered by 1,25(OH) 2 D 3 have been implicated in regulation of apoptosis, the process which can determine cell fate in health and disease, including cancer and obesity [7, 9, 10] .
Vitamin D status has been linked to several cancers and obesity in numerous observational and a limited number of mechanistic studies [6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Vitamin D deficiency/insufficiency has been associated with the increased risk of colorectal, breast, ovarian, prostate, pancreatic, skin, and other types of cancer as well as obesity; however, causality in these associations remains unproven [4, 6, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . A promising approach for the prevention and treatment of cancer and obesity is targeted, differential induction of apoptosis resulting in elimination of tumor cancer cells and reduction of the number of fat cells in adipose tissue [6-8, 11, 13, 20] . Understanding the mechanisms of vitamin D-dependent Ca 2+ -mediated apoptosis in cancer and obesity could provide a rationale for discovery of novel therapeutic and preventive modalities for these diseases.
Cancer and obesity can be considered as interrelated diseases [3, 4, 6, 11] . Epidemiological studies have shown that obesity is a significant risk factor for several cancers [6, 12, 21] , but, again, mechanisms linking obesity and cancer are not well understood. Cancer and obesity can arise as a consequence of dysregulation of common endocrine, paracrine, and intracellular signaling pathways determining the fate of both cancer cells and adipocytes [4, 6, 11, 21] . Obesity appears to increase risk of cancer via multiple mechanisms regulating proliferation, differentiation, apoptosis, inflammation, and cell signaling mediated by obesity-related hormones [including 1,25(OH) 2 D 3 ] and growth factors known to favor cancer cell promotion, progression, and tumor growth [3, 6, 11, 21] . On the other hand, risk factors for the development of cancer and obesity are determinants of vitamin D status [3, 4] .
The purpose of this review is to discuss the potential link of vitamin D status to the prevention of cancer and obesity via apoptotic mechanism as well as to elucidate the role of 1,25(OH) 2 [1, 6, 11] . Vitamin D status should be carefully defined as sufficient, insufficient, or deficient based on mechanistic studies and direct and indirect evidence-based approach. The US Institute of Medicine (IOM) [22, 23] , the Endocrine Society [24] , the European Food Safety Authority [25] , and health regulatory agencies of other European countries [26, 27] [1, 26, 29, 30] . Extra-renal production of 1,25(OH) 2 D 3 and its possible significance for paracrine/autocrine regulation of cellular functions is plausible [1, 3] , but this production does not appear to contribute to maintaining circulating 1,25(OH) 2 It is also worth mentioning that rickets and osteomalacia are observed when 25(OH)D is "undetectable" in blood (usually, it means below 0.5-5 ng/mL depending on the assay) and that the optimal bone growth and remodeling as well as maximum intestinal Ca 2+ absorption [the major physiological functions of 1,25(OH) 2 D 3 ] can be maintained in healthy individuals at 25(OH)D concentrations in the range of 10-20 ng/mL [probably, the lower limit is sufficient because it will not limit the 1,25(OH) 2 D 3 production]. In this context, claims regarding widespread vitamin D "deficiency" and benefits of measuring 25(OH)D routinely and/or in various populations should be considered critically. It is, perhaps, feasible to discuss the significance of vitamin D insufficiency at the 25(OH)D levels between 20 and 30 ng/mL [5, 28] , but it is not particularly relevant from the mechanistic and, probably, nutritional points of view. The important rationale for increasing vitamin D intake (particularly in low/insufficient sunlight conditions) and maintaining 25(OH)D concentration in the range of 30-60 ng/mL is the potential role of vitamin D in preventing certain diseases [5, 28] , but the mechanisms of these effects and associations of the effects with vitamin D status remain to a significant extent speculative. It is important to emphasize that 25(OH)D concentrations in the range of 100-150 ng/mL should be considered as increasing the risk of vitamin D toxicity. In the case of anticancer (preventive and therapeutic) effects of vitamin D, pharmacological levels of the hormone, 1,25(OH) 2 D 3 , are required [6, 13, 31, 32] , and those levels cannot be achieved with vitamin D supplementation or sunlight/UVB exposure. In pharmacological concentrations, 1,25(OH) 2 D 3 causes significant side effects (hypercalcemia), and evaluations (including clinical trials) of "noncalcemic" analogs of 1,25(OH) 2 D 3 have provided mixed or discouraging results [6, 13] .
The points discussed suggest that maintaining sufficient vitamin D status may be important for prevention of cancer and, possibly, obesity, but increasing vitamin D intake above the currently recommended levels, probably, will not provide additional health benefits. It should be also noted that vitamin D status [25(OH)D concentration in blood] can serve as an excellent marker of good health [3] and that many of the variables that contribute to 25(OH) D concentration (unhealthy dietary pattern, physical inactivity, aging, skin pigmentation) are also risk factors for the development of cancer and obesity. Therefore, mechanistic studies and clinical intervention trials are critical for resolving the uncertainty regarding potential benefits of increasing vitamin D intake for the prevention of cancer and obesity.
Vitamin D-mediated apoptosis in cancer and obesity
The hypothesis that vitamin D may be a determinant of cancer and obesity risk is plausible from a mechanistic perspective because 1,25(OH) 2 D 3 can regulate the fate of cancer cells and adipocytes via apoptosis [7, 8, 20, 33] . The apoptotic effect of vitamin D in these cells is determined by the expression of nuclear VDRs and via the role of 1,25(OH) 2 ] i and μ-calpain activation but also reduced apoptotic death triggered by 1,25(OH) 2 D 3 [13] . Similarly, the inhibition of calpain and caspase-12 activity by structurally unrelated inhibitors increased survival of the cancer cells and reduced the amount of apoptotic cells [13, 33, 36] . These results suggest that calpain and caspase-12 may take over the role of major proteases in apoptotic cell death.
The hormone 
Summary and outlook
The studies reviewed here have identified the novel apoptotic pathway in epithelial cancer cells and mature adipocytes, which is regulated by 1,25(OH) 2 ] i reaching elevated (200-500 nM) but not cytotoxic ( > 1 μM) levels -via Ca 2+ release from the ER stores and Ca 2+ entry through the VICC. μ-Calpain activation by cytosolic Ca 2+ is followed by activation (i.e., Ca 2+ -dependent translocation from the ER membrane to cytosol and calpain-dependent processing/cleavage) of the Ca 2+ /calpaindependent caspase-12. Activation of these proteases appears to be sufficient for execution of apoptosis, as evaluated by hallmarks of this process: apoptotic changes of the plasma membrane (phosphatidylserine translocation from the inner to outer surface of the plasma membrane) and DNA fragmentation/nuclear condensation. Normal mammary epithelial cells are resistant to induction of apoptosis with 1,25(OH) 2 -dependent molecular targets in apoptotic pathways in cancer and obesity [50] .
Highlights
The hormone 1,25(OH) 2 -mediated apoptotic pathway in both mature adipocytes and epithelial cancer cells presents an opportunity for simultaneous targeting of the growth and adipose microenvironment of tumors in cancer as well as expansion of adipose tissue in obesity.
The role of vitamin D in Ca
2+
-mediated apoptosis in cancer and obesity indirectly supports the recommendation to maintain optimal vitamin D status as a plausible approach for preventing some cancers and decreasing adiposity. However, sufficient vitamin D status is also an excellent marker of good health, and many of the risk factors for the development of cancer and obesity contribute significantly to low vitamin D status.
